Logo Cepheid
Demande d’information
Emplacement/Langue

{{headingText}}

{{paragraphText}}

{{continueBtnLabel}}

{{initials}}
Main Menu
Emplacement/Langue

{{headingText}}

{{paragraphText}}

{{continueBtnLabel}}

Demande d’information
Demande d’information

Xpert® MTB/RIF Ultra

Order Now
MTB/RIF Ultra computer generated depiction.

Performances améliorées pour la détection des cas de tuberculose sensibles et résistants aux antibiotiques en moins de 80 minutes

Le besoin

an ill woman listens to a physician
  • Each day, close to 4 400 people lose their lives to TB and nearly 30 000 people fall ill with this preventable and curable disease1
  • Globally, diagnosis of TB and drug-resistant TB remains a challenge, with a third of people with TB and two-thirds of people with drug-resistant TB not being detected1
  • Precise and early detection of TB is needed to improve case management and significantly enhance the prevention of TB transmission2
1 World Health Organization Tuberculosis Report 2023 - https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023
2 Centers for Disease Control and Prevention—Guidelines for preventing the transmission of TB - https://www.cdc.gov/mmwr/preview/mmwrhtml/00001897.htm

La solution

a male and a female researchers scanning cepheid test cartridges
  • Xpert MTB/RIF Ultra provides fast and highly accurate detection of Mycobacterium Tuberculosis (MTB) and Rifampicin (RIF) resistance simultaneously from patient samples
  • Higher sensitivity, especially in smear-negative TB cases and among HIV-infected patients3
  • Simple three-step process with minimal hands-on time and results in ~80 min direct from sample
  • Designed to provide highly accurate MTB and Rifampicin detection utilizing multi-target and melt curves technology
3 Aliasgar Esmail, et al, Comparison of Xpert MTB/RIF (G4) and Xpert Ultra, including trace readouts, for the diagnosis of pulmonary tuberculosis in a TB and HIV endemicsetting https://researchonline.lshtm.ac.uk/id/eprint/4661245/1/1-s2.0-S1201971220301442-main.pdf

L’impact

a smiling female doctor attends an elderly woman
  • Early detection of MTB and RIF resistance can support timely clinical decision‑making and appropriate therapy initiations4
  • IIncreased access to front‑line testing with Xpert MTB/RIF Ultra as part of active case finding and management can help support control activities5
  • Superior sensitivity to smear microscopy enables detection of more MTB‑positive patients, with results available in ~80 minutes to support prompt clinical assessment
4 Charkravorty S, et al. The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing - https://journals.asm.org/doi/10.1128/mbio.00812-17
5 Belén Saavedra, et al. Performance of Xpert MTB/RIF Ultra for tuberculosis diagnosis in the context of passive and active case finding - https://erj.ersjournals.com/content/58/6/2100257

Connecté pour de meilleurs résultats

Demande d’information

Informations

Get More Insights
Powered by Translations.com GlobalLink Web SoftwarePowered by GlobalLink Web